2024 Biomarkers & Personalized Medicine in Cardiovascular Disease Symposium

May 3, 2024


Physician Certificate


Please note required fields are marked with a red *

A value is required.
Please print your name exactly as you wish it to appear on the certificate.

A value is required.
Please print your name exactly as you wish it to appear on the certificate.

A value is required.

A value is required.The email address doesn't match.

Please select an item.



Did this activity:
Meet the stated learning objectives?

Describe the current standards of care associated with the application of biomarkers in the care of patients with acute coronary syndrome (ACS) and type 2 myocardial infarction; heart failure; as well as diabetes, pulmonary hypertension and related illnesses.


Cite recent literature that provides an evidence basis for the use of biomarkers for prediction, diagnosis, and management of cardiovascular disease.

Discuss emerging biomarker applications in cardiovascular disease based on recent breaking clinical studies and clinical trials.


Explain how new data in ACS, heart failure, diabetes, and other related diseases are pointing to biomarkers as a key tool in the emerging era of precision medicine.


Apply non-traditional biomarkers including potassium, breast arterial calcification, and pulmonary artery pressure to guide and improve the treatment of patients with (or at risk for) cardiovascular disease.


Describe recent clinical advances and the role of biomarkers in management of cardiovascular disease in women.


Apply biomarkers to help optimize selection of patients for cardiac devices, assess for response to device therapy, and improve prognostication of patients with devices.


Describe how biomarkers as well as non-invasive patient-specific markers can guide a personalized approach to management of atrial fibrillation and ventricular arrhythmias.


Identify novel mobile technologies, digital applications and technologies, and devices that are impacting patient care and personalized medicine and describe various ways they are being used.


Meet the stated overall purpose/goal for this activity? 

To provide the latest clinical data, guidelines, and evidence related to the clinical application of biomarkers in cardiovascular conditions.



Please rate each speaker on subject knowledge and effectiveness of topic on a scale 1 – 5
with 5 being of the highest quality:
     This is required to recieve credit

  1

  2

  3

  4

  5
'Martin Than, MD: hsTroponin in the Emergency Department
Please make a selection.
'Nick Mills, MD, PhD: Rethinking the Universal Definition of MI
Please make a selection.
'Fred Apple, PhD: Single Troponin Measurements to Rule out MI
Please make a selection.
'Martin Mockel, MD: Biomarkers of ACS in the Updated ESC Guidelines: Advancements and Controversies
Please make a selection.
'Kristin Aarke, MD, PhD: Point of Care hsTroponin: Dawn of a New Age
Please make a selection.
'Kristi Kulasa, MD; Cardiologists as Diabetologists: Biomarkers and SGLT2i/GLP1a
Please make a selection.
'Lori Daniels, MD: What Biomarkers Teach us About GDMT?
Please make a selection.
'Christopher deFilippi, MD: Vericiguat Optimization with Biomarkers
Please make a selection.
'Tony Urey, MD: Biomarkers in Amyloid and HCM: New Opportunities
Please make a selection.
'Palak Shah, MD5/7/2024 Are Biopsies History? Circulating ‘Omics After Heart Transplant
Please make a selection.
'Nanette Wenger, MD: Cardiovascular Disease in Women: Epidemiology, Awareness, Access, and Delivery of Equitable Healthcare
Please make a selection.
'Nathan Wong, PhD: Coronary Artery Calcification: Role in Preventive Cardiology
Please make a selection.
'Sheryl Chow, PharmD: Can Biomarkers Identify Patients at Risk for Cardiovascular Kidney Metabolic (CKM) Syndrome?
Please make a selection.
'Nathan Wong, PhD: Lipoprotein(a): Ready for Prime Time?
Please make a selection.
'Anya Narezkina, MD: Biomarkers in Cardio-Oncology
Please make a selection.
'Harpreet Bhatia, MD: Choosing the Right Lipid Lowering Agents: A Personalized Approach Using Lipid Biomarkers
Please make a selection.
'Lori Daniels, MD: Breast Arterial Calcification for Cardiovascular Risk Prediction in Women
Please make a selection.
'W. Frank Peacock, MD: More Than Skin-Deep: Transcutaneous Troponin Measurements
Please make a selection.
'Stephen Smith, MD: A Fresh Look at an Old Friend: ECGs and the Queen of Hearts
Please make a selection.
'Eldrin F. Lewis, MD, MPH: Novel Markers and Machine Learning - Moving Beyond Race for Cardiovascular Risk Prediction
Please make a selection.

 


Please indicate which of the following is true regarding this educational activity (select all that apply):


I expect that my participation in this activity will improve my:
Knowledge gained from the new information presented?


Based on your participation in this activity, do you intend to change your practice behavior?


Please specify the type of change you plan to implement, in your practice (select all that apply):







This educational activity addressed the following American Board of Medical Specialties/Institute of Medicine core competencies (select all that apply):


Please indicate any barriers you perceive in implementing changes (select all that apply):



Was this activity free of commercial bias? If no, please comment below.





As a result of this activity, please share at least one action you will take to change your professional practice/performance.


The Course Directors would appreciate any additional comments that will help shape the future of the conference including venue selection, room layout, exhibit hall, etc....:

I attest that I have completed the CME activity and I am only claiming the number of credits that are consistent with the hours of actual participation. Please select the hours of participation in the activity: Please select an item.